Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer

References

• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England J Med. 2001 03 15;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clinical Oncology. 2011 Sep 01;29(25):3366–3373. PubMed PMID: 21768458; PubMed Central PMCID: PMCPmc3164242. eng.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809–820. PubMed PMID: 16495393; eng.
   PubMed Web of Science ®Google Scholar
• Au HJ, Eiermann W, Robert NJ, et al. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 study. Oncologist. 2013;18(7):812–818. PubMed PMID: 23814044; PubMed Central PMCID: PMCPmc3720634. eng.
   PubMed Web of Science ®Google Scholar
• Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-Cancer Drugs. 2012 Sep;23(8):765–776. PubMed PMID: 22824822; eng.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer. New England J Med. 2015;372(8):724–734. PubMed PMID: 25693012.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 05;357(1):39–51. PubMed PMID: 17611206; eng.
   PubMed Web of Science ®Google Scholar
• Cho H-S, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–760.
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009 Apr;14(4):320–368. PubMed PMID: 19346299; eng.
   PubMed Web of Science ®Google Scholar
• Guerin M, Barrois M, Terrier MJ, et al. Overexpression of either c-MYC or c-erbB-2/NEU proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988;3(1):21–31. PubMed PMID: 2905033; eng.
   PubMedGoogle Scholar
• Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2011;126(1):185–192.
   PubMed Web of Science ®Google Scholar
• Ménard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node–positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19(2):329–335. PubMed PMID: 11208823.
   PubMed Web of Science ®Google Scholar
• Furrer D, Jacob S, Caron C, et al. Concordance of HER2 immunohistochemistry and fluorescence in situ hybridization using tissue microarray in breast cancer. Anticancer Res. 2017 Jun;37(6):3323–3329. PubMed PMID: 28551685; eng.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 11 01;31(31):3997–4013.
   PubMed Web of Science ®Google Scholar
• Kute T, Lack CM, Willingham M, et al. Development of Herceptin resistance in breast cancer cells. Cytometry A: Journal Int Soc Anal Cytol. 2004 Feb;57(2):86–93. PubMed PMID: 14750129; eng.
   PubMedGoogle Scholar
• Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003 PubMed PMID: 12908564; eng;532:253–268.
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006 Jan 30;94(2):259–267. PubMed PMID: 16404427; PubMed Central PMCID: PMCPmc2361112. eng.
   PubMed Web of Science ®Google Scholar
• Collins DM, O’Donovan N, McGowan PM, et al. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2012 Jul;23(7):1788–1795. PubMed PMID: 22056974; eng.
   PubMed Web of Science ®Google Scholar
• Takai N, Jain A, Kawamata N, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15;104(12):2701–2708. PubMed PMID: 16265675; eng.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Beckmann MW, Rody A, et al. HER2 dimerisation inhibitor pertuzumab - mode of action and clinical data in breast cancer. Breast Care (Basel, Switzerland). 2013 Mar;8(1):49–55. PubMed PMID: 24715843; PubMed Central PMCID: PMCPmc3971793. eng.
   PubMed Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004 Apr 01;64(7):2343–2346. PubMed PMID: 15059883; eng.
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clinical Oncology. 2005 Jul 01;23(19):4265–4274. PubMed PMID: 15911866; eng.
   PubMed Web of Science ®Google Scholar
• Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clinical Oncology. 2011 Jan 20;29(3):264–271. PubMed PMID: 21149659; eng.
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet (London, England). 2010 Jan 30;375(9712):377–384. PubMed PMID: 20113825; eng.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 06; 365(14):1273–1283. PubMed PMID: 21991949; PubMed Central PMCID: PMCPmc3268553. eng. •.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Abstract S5-04: ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→ T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→ TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Aacr. 2016;76:S5-04.
   Google Scholar
• Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005 Oct;10(9):665–685. PubMed PMID: 16249346; eng.
   PubMed Web of Science ®Google Scholar
• Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clinical Oncology. 2001 Nov 15;19(22):4216–4223. PubMed PMID: 11709565; eng.
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and Leukemia Group B protocol 9840. J Clinical Oncology. 2008 Apr 01;26(10):1642–1649. PubMed PMID: 18375893; eng.
   PubMed Web of Science ®Google Scholar
• Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent SRC/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006 Aug;41(2):228–235. PubMed PMID: 16769082; PubMed Central PMCID: PMCPmc1847613. eng.
   PubMed Web of Science ®Google Scholar
• Ponde NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 2016;1(4): e000073. PubMed PMID: 27843627; PubMed Central PMCID: PMCPmc5070246. eng.
   PubMed Web of Science ®Google Scholar
• Zeglinski M, Ludke A, Jassal DS, et al. Trastuzumab-induced cardiac dysfunction: a ‘dual-hit’. Exp Clin Cardiol. 2011 Fall;16(3):70–74. PubMed PMID: 22065936; PubMed Central PMCID: PMCPmc3209542. eng.
   PubMedGoogle Scholar
• Morris PG, Dickler M, McArthur HL, et al. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 12 20;27(36):6117–6123.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014. J Natl Compr Cancer Netw. 2014;12(4):542–590.
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Niu J, Zhang N, et al. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. J Clinical Oncology. 2015 Jul 01;33(19):2176–2183. PubMed PMID: 25964256; PubMed Central PMCID: PMCPmc4979214. eng.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109–119.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clinical Oncology. 2010 Mar 01;28(7):1138–1144. PubMed PMID: 20124182; PubMed Central PMCID: PMCPmc4979216. eng.
   PubMed Web of Science ®Google Scholar
• Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res. 2008 May 01;14(9):2710–2716. PubMed PMID: 18451236; PubMed Central PMCID: PMCPmc4406095. eng.
   PubMed Web of Science ®Google Scholar
• Smyth LM, Iyengar NM, Chen MF, et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat. 2016 Jul;158(1):91–97. PubMed PMID: 27306421; PubMed Central PMCID: PMCPmc5017157. eng.
   PubMed Web of Science ®Google Scholar
• Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clinical Oncology. 2015 Feb 10;33(5):442–447. PubMed PMID: 25547504; eng.
   PubMed Web of Science ®Google Scholar
• Yu AF, Manrique C, Pun S, et al. Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with her2-positive metastatic breast cancer. Oncologist. 2016 Apr;21(4):418–424. PubMed PMID: 26984450; PubMed Central PMCID: PMCPmc4828117. eng.
   PubMed Web of Science ®Google Scholar
• Perez EA, Lopez-Vega JM, Petit T, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016 Dec 13;18(1):126. PubMed PMID: 27955684; PubMed Central PMCID: PMCPmc5154110. eng.
   PubMedGoogle Scholar
• Andersson M, López‐Vega JM, Petit T, et al. Efficacy and safety of pertuzumab and trastuzumab administered in a single infusion bag, followed by Vinorelbine: VELVET Cohort 2 Final Results. Oncologist. 2017 Jun 07;22:1160–1168. PubMed PMID: 28592618; eng.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Ciruelos E, Peretz-Yablonski T, et al. Abstract OT1-1-02: A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE). Cancer Res. 2012;74(24 suppl 3).
   Google Scholar
• Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clinical Oncology. 2017 Jan 10;35(2):141–148. PubMed PMID: 28056202; eng.
   PubMed Web of Science ®Google Scholar
• Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 02;97(3):188–194. PubMed PMID: 15687361; eng.
   PubMedGoogle Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clinical Oncology. 2008 Feb 10;26(5):778–785. PubMed PMID: 18258986; eng.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clinical Oncology. 2012 May 20;30(15):1796–1804. PubMed PMID: 22508812; eng.
   PubMedGoogle Scholar
• Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favourable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clinical Oncology. 2011 Sep 01;29(25):3351–3357. PubMed PMID: 21788566; eng.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clinical Oncology. 2013 Oct 10;31(29):3623–3630. PubMed PMID: 24002511; eng.
   PubMed Web of Science ®Google Scholar
• Amiri-Kordestani L, Wedam S, Zhang L, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res. 2014 Nov 01;20(21):5359–5364. PubMed PMID: 25204553; eng.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25–32. PubMed PMID: 22153890; eng.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–2284. PubMed PMID: 23704196; eng.
   PubMed Web of Science ®Google Scholar
• Singh JC, Mamtani A, Barrio A, et al. Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with her2-positive early stage breast cancer: a single center experience. Oncologist. 2017 Feb;22(2):139–143. PubMed PMID: 28167568; PubMed Central PMCID: PMCPmc5330708. eng.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, De Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in Early HER2-positive breast cancer. New England J Med. 2017 Jul 13;377(2):122-131. PubMed PMID: 28581356.
   Web of Science ®Google Scholar
• Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the steep system. J Clin Oncol. 2007 05 20;25(15):2127–2132.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Anthracyclines in the treatment of cancer. An Overview. Drugs. 1997;54 Suppl 4: 1–7. PubMed PMID: 9361955; eng.
   Google Scholar
• Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res. 2008 Nov 15;14(22):7167–7172. PubMed PMID: 19010832; eng.
   PubMed Web of Science ®Google Scholar
• Iyengar NM, Smyth L, Lake D, et al. Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy. Ann Oncol. 2016;27(suppl_6):270P–270P.
   Google Scholar
• Uleer C, Yazdan-Pourfard J, Holland B, et al. Long-term partial remission with capecitabine/trastuzumab in a patient with metastatic breast cancer following progression on trastuzumab alone. Breast Care (Basel, Switzerland). 2012 Feb; 7(1):45–47. PubMed PMID: 22553472; PubMed Central PMCID: PMCPmc3335352. eng.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clinical Oncology. 2009 Apr 20;27(12):1999–2006. PubMed PMID: 19289619; eng.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273–2281. PubMed PMID: 21741829; eng.
   PubMed Web of Science ®Google Scholar
• Pirvulescu C, Uhlig M, von Minckwitz G. Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression. Breast Care (Basel, Switzerland). 2008;3(5): 364–365. PubMed PMID: 20824032; PubMed Central PMCID: PMCPmc2931110. eng.
   PubMed Web of Science ®Google Scholar
• Hammerman A, Greenberg-Dotan S, Feldhamer I, et al. Second-line treatment of her2-positive metastatic breast cancer: trastuzumab beyond progression or lapatinib? Population Based Cohort Study PloS One. 2015;10(9):e0138229. PubMed PMID: 26375590; PubMed Central PMCID: PMCPmc4574060. eng.
   PubMed Web of Science ®Google Scholar
• Jackisch C, Welslau M, Schoenegg W, et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in Germany. Breast (Edinburgh, Scotland). 2014 Oct;23(5):603–608. PubMed PMID: 25012046; eng.
   PubMed Web of Science ®Google Scholar
• Li H, Shao B, Yan Y, et al. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. Chin J Cancer Res. 2016 Jun;28(3):330–338. PubMed PMID: 27478318; PubMed Central PMCID: PMCPmc4949278. eng.
   PubMed Web of Science ®Google Scholar
• Martinez-Janez N, Chacon I, De Juan A, et al. Anti-HER2 therapy beyond second-line for HER2-positive metastatic breast cancer: a short review and recommendations for several clinical scenarios from a spanish expert panel. Breast Care (Basel, Switzerland). 2016 Apr;11(2):133–138. PubMed PMID: 27239176; PubMed Central PMCID: PMCPmc4881249. eng.
   PubMed Web of Science ®Google Scholar
• Thallinger C, Lang I, Kuhar CG, et al. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial. BMC Cancer. 2016 Feb 18;16:121. PubMed PMID: 26887956; PubMed Central PMCID: PMCPmc4758093. eng.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):689–699. PubMed PMID: 24793816; eng.
   PubMed Web of Science ®Google Scholar
• Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 May 16;18(6): 732–742. PubMed PMID: 28526536; eng.
   PubMed Web of Science ®Google Scholar
• Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncology. 2016 Jan;2(1):19–21. PubMed PMID: 26501848; eng. ••.
   PubMed Web of Science ®Google Scholar
• Goulart BH. Value: the next frontier in cancer care. Oncologist. 2016 Jun;21(6):651–653. PubMed PMID: 27226360; PubMed Central PMCID: PMCPmc4912371. eng.
   PubMed Web of Science ®Google Scholar
• Durkee BY, Qian Y, Pollom EL, et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clinical Oncology. 2016 Mar 20;34(9):902–909. PubMed PMID: 26351332; PubMed Central PMCID: PMCPMC5070553. online at. Author contributions are found at the end of this article. eng. • www.jco.org
   PubMed Web of Science ®Google Scholar
• Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol. 2010 07 20;28(21):3407–3410.
   PubMed Web of Science ®Google Scholar
• Yu AF, Singh JC, Wang R, et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist. 2017Jun;22(6):642–647. PubMed PMID: 28341761; eng.
   Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791–800. PubMed PMID: 27179402; eng.
   PubMed Web of Science ®Google Scholar
• De Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137–1146. PubMed PMID: 25130998; eng.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase iii adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clinical Oncology. 2016 Apr 01;34(10):1034–1042. PubMed PMID: 26598744; PubMed Central PMCID: PMCPmc4872016. eng.
   PubMed Web of Science ®Google Scholar